log in
Print | Back

Haynes and Boone, LLP

Yifang Zhao

Yifang Zhao



  • Chemical
  • Hatch-Waxman/ANDA
  • Healthcare and Life Sciences
  • Intellectual Property

WSG Practice Industries


Yifang Zhao is an associate in the Intellectual Property Litigation Practice Group in the Washington, D.C. office of Haynes and Boone. In addition to engaging in various issues in patent infringement, trade secret misappropriation, and USPTO proceedings, her practice focuses on intellectual property issues related to pharmaceutical development and commercialization, from pre-suit analysis to litigation under the Hatch-Waxman Act.

Yifang has also managed patent portfolios for biotech companies, drafted patent applications and response to PTO communications, and analyzed validity and infringement issues relating to utility and design patents and trademarks.

Prior to law school, Yifang had significant experience in the field of cardiovascular extracellular protein research, and worked as a research scientist for a multinational agrochemical biotechnology corporation. She also volunteered in Tibet, worked, and studied in Asia and Europe.

Bar Admissions

California; District of Columbia


J.D., Washington University in St. Louis School of Law, 2014
B.A., Chemistry (Biochemistry) and Psychology, Minor in Business, Washington University in St. Louis, 2009
Areas of Practice

Chemical | Hatch-Waxman/ANDA | Healthcare and Life Sciences | Intellectual Property | International | Litigation


AIA On-Sale Bar, Otherwise Reinterpreted
Haynes and Boone, LLP, December 2018

The U.S. Supreme Court heard oral arguments on December 4, 2018, inHelsinn Healthcare SA v. Teva Pharmaceuticals USA Inc.as to whether the “on-sale” bar under the America Invents Act (“AIA”) renders an inventor’s private sale to a third party as prior art for purposes of determining patentability. 35 U.S.C...

The Bitter and the Sweet: Potential Split on Constitutionality of Inter Partes Patent Review
Haynes and Boone, LLP, November 2017

Is a defeated patentee atInter PartesReview an embittered citizen whose private rights were taken without due process by a government agency lacking requisite Article III guarantees of impartiality? Or is the public getting a sweet deal when the Patent Trials and Appeals Board (PTAB) eliminates or revokes a public right that was wrongfully granted in the first place? The Supreme Court wrestled with the constitutionality ofInter PartesReview during oral argument on Monday morning, and the

The Biologics Tango: Reading Tea Leaves on the Patent Dance and Pre-Marketing Notice Requirements
Haynes and Boone, LLP, April 2017

On Wednesday, April 26, 2017, the Supreme Court heard oral argument in Sandoz Inc. v. Amgen Inc. et al., a landmark case that many hope will provide clarity and guidance for consumers and the pharmaceutical industry on the regulatory approval pathway for biosimilar drugs under the Biologics Price Competition and Innovation Act of 2009 (“BPCIA” or “Biosimilars Act”)...

WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | PRIVACY POLICY | DISCLAIMER |  © World Services Group, 2020